In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Nicox SA, with a price target of €1.50.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors including Nicox SA’s strong financial position and promising pipeline developments. The company reported a revenue of €1.7M for the first half of 2025, surpassing expectations, and has a cash runway extending over 12 months, which is bolstered by recent license and milestone payments. Additionally, Nicox is on track with its U.S. NDA submission for NCX 470, anticipated in the first half of 2026, with subsequent submissions planned for China.
Furthermore, the positive results from the Phase 3 Denali trial for NCX 470 in glaucoma, which achieved its primary endpoint, reinforce the potential for future success. This success has already triggered a €5M milestone payment from their partner Kowa. The ongoing Phase 3 program in Japan and the potential for recurrent revenue from 2027, alongside additional milestone payments and royalties, contribute to a positive outlook for Nicox, justifying the Buy rating and a price target of €1.50.
Selvaraju covers the Healthcare sector, focusing on stocks such as Bioxcel Therapeutics, Emergent Biosolutions, and Vanda. According to TipRanks, Selvaraju has an average return of 24.3% and a 55.73% success rate on recommended stocks.